grepcent public filings, reorganized for comparison

NEBIVOLOL HYDROCHLORIDE — FDA application ANDA203659

Application ANDA203659 · type ANDA · FDA status: approved · original approval 2015-04-16

Listed sponsor: ANI PHARMS · ANIP company profile · exact_unique

Sponsor as listed in Drugs@FDA at retrieval (2026-08-07); FDA sponsor listings can lag ownership transfers.

FDA application facts

ProductFDA-listed trade nameActive ingredientDosage formRouteStrengthMarketing statusTE codeRLD
001NEBIVOLOL HYDROCHLORIDENEBIVOLOL HYDROCHLORIDETABLETORALEQ 2.5MG BASEPrescriptionABNo
002NEBIVOLOL HYDROCHLORIDENEBIVOLOL HYDROCHLORIDETABLETORALEQ 5MG BASEPrescriptionABNo
003NEBIVOLOL HYDROCHLORIDENEBIVOLOL HYDROCHLORIDETABLETORALEQ 10MG BASEPrescriptionABNo
004NEBIVOLOL HYDROCHLORIDENEBIVOLOL HYDROCHLORIDETABLETORALEQ 20MG BASEPrescriptionABNo

Product, form, strength, reference-drug and marketing-status fields: Drugs@FDA data files; TE and RLD fields: Orange Book data files. Retrieved 2026-08-07.

Orange Book patent and exclusivity listings

No Orange Book patent or exclusivity listings joined to this application.

Compound cross-links

Ingredient–compound links use FDA openFDA/GSRS identifiers and an exact lmmol InChIKey join. Ingredient names cannot create a link.

Related pages

Sponsor company · FDA-approved application index

Peer clusters: No published peer-cluster link for this sponsor.

Sources: Drugs@FDA · Orange Book · openFDA application record. FDA data retrieved 2026-08-07.

Regulatory listing data as published by FDA; not medical or investment advice.